[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].

Abstract

Chronic obstructive pulmonary disease (COPD) is a disease which is characterized with progressive airflow obstruction and abnormal inflammatory response caused by noxious gases and particles. Recently oral phosphodiesterase-4 (PDE-4) inhibitors which block activation of inflammatory cells, are experimented as a new approach. Last studies showed that these drugs improve symptoms, pulmonary functions and quality of life, reduce the numbers of acute attacks, suppress bronchial inflammation in COPD. However these drugs lead to adverse reactions such as vomiting, diarrhea and headache. In this review we discussed roflumilast (Daxas) which was accepted by Food and Drug Administration (FDA), included in treatment of sever COPD in "The Global Initiative for Chronic Obstructive Lung Disease (GOLD)" guideline.

• Authors: Cengizhan Sezgi, Abdurrahman Şenyiğit
• Journal: Tuberkuloz ve toraks (Tuberk Toraks) Vol. 59 Issue 3 Pg. 285-90 ( 2011) ISSN: 0494-1373 [Print] Turkey
• Vernacular Title: KOAH'da yeni tedavi seçeneği: Fosfodiesteraz-4 inhibitörleri.
• PMID: 22087527 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Aminopyridines
• Anti-Inflammatory Agents, Non-Steroidal
• Benzamides
• Cyclopropanes
• Phosphodiesterase 4 Inhibitors
• Roflumilast

Topics

• Administration, Oral
• Aminopyridines (adverse effects, therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Benzamides (adverse effects, therapeutic use)
• Cyclopropanes (adverse effects, therapeutic use)
• Humans
• Inflammation (drug therapy, etiology)
• Phosphodiesterase 4 Inhibitors (adverse effects, therapeutic use)
• Practice Guidelines as Topic
• Pulmonary Disease, Chronic Obstructive (drug therapy)